Literature DB >> 33299826

Impact and clinical usefulness of genetic data in the surgical management of colorectal cancer liver metastasis: a narrative review.

Georgios Antonios Margonis1,2, Martin E Kreis2, Jaeyun Jane Wang1, Carsten Kamphues2, Christopher L Wolfgang1, Matthew J Weiss3.   

Abstract

IMPORTANCE: In patients who undergo surgery for colorectal cancer liver metastases (CRLM), a number of somatic mutations have been associated with worse overall (OS) and recurrence-free survival (RFS). Although useful, an association with prognosis does not necessarily equate to an impact on surgical management.
OBJECTIVE: The aim of this review was to investigate whether the best-studied somatic mutations impact surgical management of CRLM by informing: (I) post-hepatectomy surveillance; (II) selection of surgical technique; (III) selection of optimal margin width; and (IV) selection of patients for surgery. Lastly, we discuss the refinement of genetic data from overall mutation status to specific variants, as well as lesser studied somatic mutations. EVIDENCE REVIEW: We conducted a computerized search using PubMed and Google Scholar for reports published so far, using mesh headings and keywords related to genetic data and CRLM.
FINDINGS: Genetic data may impact surgical management of CRLM in three ways. Firstly, KRAS mutations can predict lung recurrences. Secondly, KRAS mutations may help tailor margin width. Thirdly, KRAS mutations may help tailor surgical technique.
CONCLUSIONS: Although genetic data may impact post-hepatectomy surveillance, selection of surgical technique and optimal margin width, their use to guide surgical selection remains elusive, as the data cannot support denying surgery to patients according to their somatic mutation profile. 2020 Hepatobiliary Surgery and Nutrition. All rights reserved.

Entities:  

Keywords:  BRAF; KRAS; P53; PIK3CA; SMAD-4; Somatic mutations; colorectal liver metastases

Year:  2020        PMID: 33299826      PMCID: PMC7720057          DOI: 10.21037/hbsn.2019.10.05

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


  44 in total

Review 1.  KRAS Alleles: The Devil Is in the Detail.

Authors:  Kevin M Haigis
Journal:  Trends Cancer       Date:  2017-09-12

2.  RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.

Authors:  Jean-Nicolas Vauthey; Giuseppe Zimmitti; Scott E Kopetz; Junichi Shindoh; Su S Chen; Andreas Andreou; Steven A Curley; Thomas A Aloia; Dipen M Maru
Journal:  Ann Surg       Date:  2013-10       Impact factor: 12.969

3.  Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.

Authors:  Jeremy C Jones; Lindsay A Renfro; Humaid O Al-Shamsi; Alexa B Schrock; Andrew Rankin; Ben Y Zhang; Pashtoon M Kasi; Jesse S Voss; Alexis D Leal; James Sun; Jeffrey Ross; Siraj M Ali; Joleen M Hubbard; Benjamin R Kipp; Robert R McWilliams; Scott Kopetz; Robert A Wolff; Axel Grothey
Journal:  J Clin Oncol       Date:  2017-05-09       Impact factor: 44.544

Review 4.  Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases.

Authors:  K W Brudvik; S E Kopetz; L Li; C Conrad; T A Aloia; J-N Vauthey
Journal:  Br J Surg       Date:  2015-07-21       Impact factor: 6.939

5.  SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases.

Authors:  Takashi Mizuno; Jordan M Cloyd; Diego Vicente; Kiyohiko Omichi; Yun Shin Chun; Scott E Kopetz; Dipen Maru; Claudius Conrad; Ching-Wei D Tzeng; Steven H Wei; Thomas A Aloia; Jean-Nicolas Vauthey
Journal:  Eur J Surg Oncol       Date:  2018-03-07       Impact factor: 4.424

6.  Higher Tumor Burden Neutralizes Negative Margin Status in Hepatectomy for Colorectal Cancer Liver Metastasis.

Authors:  Masanori Oshi; Georgios Antonios Margonis; Yu Sawada; Nikolaos Andreatos; Jin He; Takafumi Kumamoto; Daisuke Morioka; Christopher Lee Wolfgang; Kuniya Tanaka; Matthew John Weiss; Itaru Endo
Journal:  Ann Surg Oncol       Date:  2018-11-27       Impact factor: 5.344

7.  Impact of Metastasectomy in the Multimodality Approach for BRAF V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience.

Authors:  Benny Johnson; Zhaohui Jin; Mark J Truty; Rory L Smoot; David M Nagorney; Michael L Kendrick; Benjamin R Kipp; Axel Grothey
Journal:  Oncologist       Date:  2017-09-13

8.  Recurrence After Liver Transplantation for Hepatocellular Carcinoma: A New MORAL to the Story.

Authors:  Karim J Halazun; Marc Najjar; Rita M Abdelmessih; Benjamin Samstein; Adam D Griesemer; James V Guarrera; Tomoaki Kato; Elizabeth C Verna; Jean C Emond; Robert S Brown
Journal:  Ann Surg       Date:  2017-03       Impact factor: 12.969

9.  Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients.

Authors:  Johan Gagnière; Aurélien Dupré; Sepideh S Gholami; Denis Pezet; Thomas Boerner; Mithat Gönen; Thomas P Kingham; Peter J Allen; Vinod P Balachandran; Ronald P De Matteo; Jeffrey A Drebin; Rona Yaeger; Nancy E Kemeny; William R Jarnagin; Michael I D'Angelica
Journal:  Ann Surg       Date:  2020-01       Impact factor: 12.969

10.  Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.

Authors:  Stéphane Renaud; Pierre-Emmanuel Falcoz; Mickaël Schaëffer; Dominique Guenot; Benoit Romain; Anne Olland; Jérémie Reeb; Nicola Santelmo; Marie-Pierre Chenard; Michèle Legrain; Anne-Claire Voegeli; Michèle Beau-Faller; Gilbert Massard
Journal:  Br J Cancer       Date:  2015-09-15       Impact factor: 7.640

View more
  1 in total

1.  Fat signal fraction assessed with MRI predicts hepatic recurrence following hepatic resection for colorectal liver metastases.

Authors:  Nozomu Sakai; Koichi Hayano; Takashi Mishima; Katsunori Furukawa; Tsukasa Takayashiki; Satoshi Kuboki; Shigetsugu Takano; Yohei Kawasaki; Hisahiro Matsubara; Masayuki Ohtsuka
Journal:  Langenbecks Arch Surg       Date:  2022-04-01       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.